Samsung Medison S-Fusion technology succeeds in biopsy procedure at Seoul National University Bundang Hospital

Samsung Medison announced on the 8th that it had successfully performed a biopsy procedure using ‘S-Fusion™’ technology at Seoul National University Bundang Hospital. This is the first time since S-Fusion technology was registered in the new medical technology recognized by the Health Insurance Review and Assessment Service.

S-Fusion is a technology independently developed by Samsung Medison to further improve the accuracy of ultrasound/MRI fusion prostate biopsy. Biopsy uses a method of extracting tissue by targeting the suspected lesion area while viewing the ultrasound and MRI images together.

This method improves cancer diagnosis accuracy by about 10% and reduces the probability of re-examination of biopsy compared to when MRI is not used, reducing the pain of patients.

Samsung Medison significantly improved the registration accuracy by applying a technology to correct the prostate shape in the MRI image by referring to the prostate ultrasound image shape pressed by the pressure of the probe inserted into the anus.

According to the clinical research results of Seoul National University Bundang Hospital, when S-Fusion is used, the ultrasound/MRI image registration error is reduced by 60%, from an average of 5.32 mm to 2.11 mm, compared to when the target biopsy was performed without correcting the shape of the MRI prostate image, improving the examination accuracy. could be raised

Won-cheol Bang, managing director of Samsung Medison, said, “Prostate cancer is the fourth most common cancer in men and the seventh in death rate, and is increasing every year. We look forward to contributing more.”

Reporter Bongkyun Ham hbkone@etnews.com